The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2016

Filed:

Nov. 02, 2006
Applicants:

John H. Sampson, Durham, NC (US);

Darell D. Bigner, Mebane, NC (US);

Duane Mitchell, Durham, NC (US);

Amy Heimberger, Houston, TX (US);

Inventors:

John H. Sampson, Durham, NC (US);

Darell D. Bigner, Mebane, NC (US);

Duane Mitchell, Durham, NC (US);

Amy Heimberger, Houston, TX (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/08 (2006.01); A61K 39/00 (2006.01); A61K 47/48 (2006.01); C07K 14/435 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); A61K 39/0005 (2013.01); A61K 39/0011 (2013.01); A61K 47/48284 (2013.01); C07K 14/43504 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/6081 (2013.01); C07K 2319/00 (2013.01);
Abstract

The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, hi fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.


Find Patent Forward Citations

Loading…